Galectin Therapeutics adds two directors to board
This article was originally published in Scrip
Executive Summary
Galectin Therapeutics has appointed Kevin Freeman and John Mauldin as directors on its board, bringing the total number of board members to 11. Mr Freeman is currently president of Cross Consulting Services and chief investment officer of Capitalist Publishing. Mr Mauldin is currently president of Millenium Wave Advisors.